The video explains the process of the advancement of a radiopharmaceutical for imaging of Alzheimer ´ s illness with positron emission tomography. The toxin epibatidine, which was initially stemmed from a toxin arrow frog, is known to bind to different subtypes of nicotinic acetylcholine receptors. Those with an alpha1 subunit are primarily accountable for the toxic action, those with alpha4 and alpha7 subunits are essential for Alzheimer ´ s disease. Structural adjustment enabled avoidance of the toxic action. The brand-new particle, called flubatine, includes fluorine in 6-position of a pyridine which was exchanged by the cyclotron-produced positron emitter fluorine-18. Effective in vitro and preclinical in vivo characterization on the nanoScan PET/MRI (Mediso, Hungary; http://www.medisousa.com/preclinical/nanoscan/pet-mri) of the radiolabelled flubatine permitted radiopharmaceutical production and usage of the substance for ANIMAL imaging of patients with Alzheimer ´ s illness.
Recorded at the Helmholtz-Zentrum Dresden-Rossendorf Research Site Leipzig (www.hzdr.de) and Universität Leipzig (www.uni-lepizig.de).
Associated post: Löser, R.; Fischer, S.; Hiller, A.; Köckerlin, M.; Funke, U.; Maisonial,. A.; Brust, P.; Steinbach, J., Beilstein J. Org. Chem. 2013, 9, 1002-1011. 10.3762/ bjoc.9.115 (http://dx.doi.org/10.3762/bjoc.9.115).
Credits: Beilstein TV (http://www.beilstein.tv/tvpost/toxic-epibatidine-was-structurally-modified-to-image-alzheimer%C2%B4s-disease/).